Microsoft customers worldwide can now discover Vertex Configuration Agent through Microsoft Marketplace, accessing trusted solutions that accelerate innovation and business transformation with unified integration across Microsoft productsKING OF PRUSSIA, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced the availability of Vertex Configuration Agent for Microsoft Dynamics 365 in the Microsoft Mar ...

Vertex, Inc. (NASDAQ:VERX) is included in our list of the overlooked tech stocks to invest in. Goldman Sachs Remains Bullish on Vertex (VERX) After Q3 2025 Results Vertex, Inc. (NASDAQ:VERX) experienced a price target cut on November 5, 2025, with Goldman Sachs lowering its target from $43 to $28, while reiterating a “Buy” rating. The price revision reflects short-term headwinds, such as customer bankruptcies and rapid cloud migrations. However, Goldman Sachs’ price target cut came amid positive analyst ...

Core Insights - Vertex Pharmaceuticals announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the RUBY-3 trial at the ASN Kidney Week 2025 [1] Group 1: Drug Information - Pove is an investigational recombinant fusion protein therapeutic [1] - Pove acts as a dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines [1]

Summary of Key Points Core Viewpoint - BofA has lowered the price target for Vertex (VERX) to $24 from $34, maintaining a Neutral rating due to a disappointing Q4 outlook [1]. Company Performance - The implied growth rate for Q4 is projected at 9%, which is at the low end of the industry growth range of 8% to 12% [1]. - The firm suggests that the acceleration of growth is dependent on the success of cross-selling the e-invoicing offering [1].

Key Points The tax software specialist delivered double-digit growth on the top line in its latest quarter. Adjusted net income also rose, albeit not as steeply. 10 stocks we like better than Vertex › The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly earnings report that many considered to be underwhelming. By contrast, the benchmark S&P 500 index rose on the ...

Core Insights - Vertex Pharmaceuticals (VRTX) reported adjusted earnings of $4.80 per share for Q3 2025, exceeding the Zacks Consensus Estimate of $4.55, with a year-over-year earnings increase of approximately 10% [1][10] - Total revenues reached $3.08 billion, surpassing the Zacks Consensus Estimate of $3.04 billion, marking an 11% year-over-year growth driven by Trikafta/Kaftrio sales and contributions from new drugs [1][10] Revenue Breakdown - U.S. revenues rose 15% year over year to $1.98 billion, fueled by strong demand and favorable net pricing, alongside contributions from new products [2] - International sales increased 4% to $1.10 billion, supported by strong cystic fibrosis (CF) growth and contributions from Casgevy [2] - Trikafta generated $2.65 billion in sales, a 2.6% increase year over year, outperforming estimates [2][10] - Alyftrek sales reached $247 million in Q3, up from $156.8 million in Q2, with strong U.S. launch progress and early success in European markets [3] - Revenues from other products declined 6% year over year to $175.8 million, including contributions from Casgevy and Journavx [4] Product Performance - Casgevy sales were $16.9 million, down 44.4% sequentially, with expectations of over $100 million in revenues for the year and significant growth anticipated in 2026 [5] - Journavx generated $19.6 million in sales, up from $12 million in Q2, following its U.S. approval in January [6] Cost and Expense Analysis - Adjusted R&D expenses increased 12.6% year over year to $861.1 million to support pipeline development [7] - Adjusted SG&A expenses rose 23% to $369 million, reflecting costs associated with the launch of Journavx [7] - Adjusted operating income rose 6% to $1.38 billion [8] Guidance and Future Outlook - Vertex tightened its total revenue guidance for 2025 to a range of $11.9 billion to $12.0 billion, indicating growth of 8-9% driven by CF franchise growth and contributions from new products [10][11] - Combined adjusted R&D, AIPR&D, and SG&A expense guidance for 2025 was raised to $5.0 billion to $5.1 billion [12] - The adjusted tax rate was reduced to a range of 17% to 18% [12] Market Reaction and Competitive Landscape - Despite strong Q3 results, Vertex shares declined 4% in after-hours trading, likely due to the disappointing sales performance of Casgevy [13] - Year-to-date, Vertex shares have risen 5.8%, compared to the industry's 12.1% increase [13] - Vertex's CF sales continue to grow, but there are concerns regarding the slower uptake of Casgevy and dependence on the CF franchise for revenue [14][17]

A downtrend has been apparent in Vertex (VERX) lately with too much selling pressure. The stock has declined 17.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...

Core Insights - Vertex, Inc. is a leading provider of tax technology solutions, offering software and services to streamline tax processes for businesses [1] - Jefferies analyst Samad Samana has set a price target of $28 for Vertex, indicating a potential upside of 35.33% from its current price of $20.69 [1][5] - The company has faced challenges, evidenced by a 10% decline in stock price following mixed third-quarter results, raising investor concerns [2][5] Stock Performance - Vertex's stock price is currently at $20.69, reflecting a decrease of 9.65% or $2.21 [2] - The stock has shown significant volatility, with a daily trading range between $19.29 and $22.95 [3] - Over the past year, Vertex reached a high of $60.71 and a low of $19.29, indicating substantial fluctuations in investor sentiment [3][5] Market Activity - Vertex has a market capitalization of approximately $3.3 billion [3] - The trading volume on NASDAQ is 5,794,457 shares, indicating active trading and interest in the company [4]

Core Insights - Vertex (NASDAQ: VERX) reported mixed results, leading to varied interpretations among investors [1] Financial Performance - The company delivered a split result, indicating discrepancies in financial metrics that may affect investor sentiment [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-208 ...